
The Alliance for mRNA Medicines is the first and only scientific and policy organization singularly focused on advancing and advocating for global mRNA innovation.

The Alliance for mRNA Medicines is the first and only scientific and policy organization singularly focused on advancing and advocating for global mRNA innovation.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

Hernandez details how the non-profit organization advocates for improved access to care at the community, state, and federal levels, and amplifies education and awareness efforts within its social media communities.

Building on Organon’s prior FP2030 commitment, the company announces $30 million in new funding to fuel global action and community-driven solutions needed by the 121 million women and girls who experience unplanned pregnancies each year.

Nelarabine Injection ensures access to a lifesaving treatment, particularly for children, that historically has been in shortage.

Standard Media Index's latest data suggests that 2022 may have been a tipping point in the transition to digital pharma advertising.

Pharmaceutical companies are increasingly using radio advertising, both traditional and digital.

Survey: HCPs Rank Corporate Reputation as Leading Factor After Drug Efficacy and Safety

Enterprise generative AI focused on life sciences to bring life-saving drugs to market faster.

The drug is Xspray Pharma's first innovative cancer therapy and is set to launch later in 2023.

Blueprint Medicines Corporation will regain global commercialization and development rights to Gavreto (pralsetinib).

The therapy to treat a type of inherited bleeding disorder known as hemophilia A is expected to launch in the United States in April.

Wall Street Journal reports psychedelic-therapy industry gets a reality trip as investors focus on treatments costing less time and money

Bausch + Lomb has launched a social media campaign called "What Sight Inspires You" to raise awareness of age-related macular degeneration.

Sermo and LiveWorld survey of 50+ pharma marketers and 200+ physicians finds that social media plays a major role in influencing perceptions of medications, prescribing Habits, ongoing medical education and professional networking.

The capabilities will support life sciences organizations with a variety of use cases, including health care provider (HCP) interactions, HCP education, and patient education.

Pharm Exec spoke with Skalicky about new ways that life sciences companies are engaging with outsourcing.

A new study shows that a growing number of younger generations are turning to social media platforms such as TikTok and Instagram influencers for health advice.

Move enables FINN to address pressing health priorities in developed and developing nations and expands Hyderus global service capabilities and client offerings and Hyderus co-founders Mark Chataway and Christopher Nial join FINN global health leaders team.

Takeda's partnership with Novavax to manufacture 150 million doses of COVID-19 vaccine has been heavily impacted.

AstraZeneca is forecasting growth in 2023 and beyond, relying on its expanding line of cancer, metabolic, and rare disease drugs to offset declining COVID product sales.

Pharm Exec spoke with the senior vice president and vice president and therapeutic area head of global medical, inflammation & representation in clinical research at Amgen about how important health equity is to the entire industry.

BMS launched a new direct-to-consumer (DTC) campaign for SOTYKTU™ (deucravacitinib) for the plaque psoriasis community.

U.S. Food and Drug Administration has greenlighted the use of Trodelvy for a third indication.

Sysnav Healthcare and Roche enter a partnership to facilitate development of industry standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology based on Sysnav's technology.

"AH-ha!™ It's Acne Hormones" features people affected by acne and highlights "AH-ha" moments to "pop" common acne myths and misconceptions.

Launch Ready from Day One is designed to empower a company's customer facing teams to drive demand, simplify access, and create a seamless and more integrated customer experience.

Pete O'Heeron, founder, chairman, and CEO of FibroBiologics, explains the key principles that biotechnology companies should follow.

New structure strengthens offerings and drives the addition of diversified marketing services.

Adding more than 100 employees to its team in 2022, the company's growth has outpaced growth in the broader healthcare advertising segment, as pharmaceutical marketers increasingly embrace digital advertising, particularly on CTV.